- Home
- ANGH vs KRON Comparison
ANGH vs KRON Comparison
Compare ANGH & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- KRON
- Stock Information
- Founded
- ANGH 2012
- KRON 2017
- Country
- ANGH United Arab Emirates
- KRON United States
- Employees
- ANGH N/A
- KRON N/A
- Industry
- ANGH Telecommunications Equipment
- KRON Medicinal Chemicals and Botanical Products
- Sector
- ANGH Consumer Discretionary
- KRON Health Care
- Exchange
- ANGH Nasdaq
- KRON Nasdaq
- Market Cap
- ANGH 51.4M
- KRON 60.3M
- IPO Year
- ANGH N/A
- KRON 2020
- Fundamental
- Price
- ANGH $0.73
- KRON $0.91
- Analyst Decision
- ANGH
- KRON Buy
- Analyst Count
- ANGH 0
- KRON 3
- Target Price
- ANGH N/A
- KRON $1.63
- AVG Volume (30 Days)
- ANGH 14.9K
- KRON 173.3K
- Earning Date
- ANGH 12-24-2024
- KRON 11-13-2024
- Dividend Yield
- ANGH N/A
- KRON N/A
- EPS Growth
- ANGH N/A
- KRON N/A
- EPS
- ANGH N/A
- KRON N/A
- Revenue
- ANGH $41,380,440.00
- KRON $9,864,000.00
- Revenue This Year
- ANGH N/A
- KRON $52.58
- Revenue Next Year
- ANGH N/A
- KRON N/A
- P/E Ratio
- ANGH N/A
- KRON N/A
- Revenue Growth
- ANGH N/A
- KRON 146.56
- 52 Week Low
- ANGH $0.71
- KRON $0.69
- 52 Week High
- ANGH $2.85
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- ANGH 40.13
- KRON 49.45
- Support Level
- ANGH $0.71
- KRON $0.84
- Resistance Level
- ANGH $0.78
- KRON $0.88
- Average True Range (ATR)
- ANGH 0.05
- KRON 0.05
- MACD
- ANGH 0.00
- KRON 0.00
- Stochastic Oscillator
- ANGH 21.44
- KRON 58.17
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with the catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner and is continuously licensing new content.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.